TRIS PHARMA, INC.
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2000-01-01
- Employees
- 251
- Market Cap
- -
- Website
- http://www.trispharma.com
Clinical Trials
22
Trial Phases
4 Phases
Drug Approvals
26
Drug Approvals
- Prev
- 1
- 2
- 3
- Next
Clinical Trials
Distribution across different clinical trial phases (22 trials with phase data)• Click on a phase to view related trials
A Study of Cebranopadol for the Treatment of Acute Pain After Abdominoplasty
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Tris Pharma, Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT06545097
- Locations
- 🇺🇸
ALLEVIATE 1 Site 001106, Little Rock, Arkansas, United States
🇺🇸ALLEVIATE 1 Site 001112, Miami, Florida, United States
🇺🇸ALLEVIATE 1 Site 001110, Bellaire, Texas, United States
A Study to Assess the Abuse Potential of Intranasal Cebranopadol
- Conditions
- Abuse, Drug
- Interventions
- Drug: Cebranopadol- 600 ugDrug: Cebranopadol- 1000ugDrug: Treatment CDrug: QualificationDrug: Cebranopadol- 800ugDrug: Treatment B
- First Posted Date
- 2024-06-11
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Tris Pharma, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT06453265
- Locations
- 🇺🇸
Ohio Clinical Trials, Inc., Columbus, Ohio, United States
A Study of Cebranopadol for the Treatment of Acute Pain After Bunionectomy
- First Posted Date
- 2024-05-21
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Tris Pharma, Inc.
- Target Recruit Count
- 240
- Registration Number
- NCT06423703
- Locations
- 🇺🇸
Alleviate 2 001113, Houston, Texas, United States
🇺🇸ALLEVIATE 2 Site 001111, San Antonio, Texas, United States
🇺🇸ALLEVIATE 2 Site 001108, Sheffield, Alabama, United States
Cebranopadol Effects on Ventilatory Drive, Central Nervous System (CNS) and Pain.
- Conditions
- Pain
- Interventions
- First Posted Date
- 2022-08-08
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- Tris Pharma, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT05491785
- Locations
- 🇳🇱
Centre for Human Drug Research (CHDR), Leiden, Netherlands
🇳🇱Leiden University Medical Centre (LUMC), Leiden, Netherlands
Assessment of Abuse Potential of Cebranopadol in Humans
- Conditions
- Human Abuse Potential
- Interventions
- First Posted Date
- 2022-02-25
- Last Posted Date
- 2022-07-27
- Lead Sponsor
- Tris Pharma, Inc.
- Target Recruit Count
- 38
- Registration Number
- NCT05256108
- Locations
- 🇺🇸
Ohio Clinical Trials, Columbus, Ohio, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- Next
News
Onyda XR, First Liquid Non-Stimulant for ADHD, Now Available in the US
Tris Pharma's Onyda XR (clonidine hydrochloride), the first liquid, non-stimulant medication for ADHD, is now available in the U.S. for pediatric patients aged 6 and older.
Cebranopadol Shows Promise in Phase 3 Trial for Acute Pain Management
Tris Pharma's cebranopadol significantly reduced pain intensity in patients following abdominoplasty in the ALLEVIATE-1 Phase 3 trial.